Page 97 - Haematologica-5

IDH1/2 mutant allele burden in AML
2016;30(11):2254–2258.
20. Boissel N, Nibourel O, Renneville A, et al.
Prognostic impact of isocitrate dehydroge- nase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol. 2010;28(23):3717–3723.
21. Boissel N, Nibourel O, Renneville A, Huchette P, Dombret H, Preudhomme C. Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood. 2011;117(13): 3696–3697.
22. Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079–1089.
23. Chou W-C, Peng K-Y, Lei W-C, et al. Persistence of mutant isocitrate dehydroge- nase in patients with acute myeloid leukemia in remission. Leukemia. 2012;26(3):527–529.
24. Jeziskova I, Razga F, Toskova M, et al. Quantitative detection of IDH2 mutation for minimal residual disease monitoring in patients with acute myeloid leukemia and its comparison with mutations in NPM1 gene. Leuk Lymphoma. 2013;54(4):867–870.
25. Debarri H, Lebon D, Roumier C, et al. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. Oncotarget. 2015;6 (39):42345–42353.
26. Brambati C, Galbiati S, Xue E, et al. Droplet digital polymerase chain reaction for DNMT3A and IDH1/2 mutations to
improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation. Haematologica. 2016;101(4):e157-161.
27. Ward PS, Patel J, Wise DR, et al. The com- mon feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting a-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17(3):225–234.
28. Pollyea DA, Kohrt HE, Zhang B, et al. 2- hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. Leuk Lymphoma. 2013;54(2):408–410.
29. Janin M, Mylonas E, Saada V, et al. Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol. 2014;32(4):297–305.
30. Shlush LI, Zandi S, Mitchell A, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014;506(7488):328– 333.
31. Klco JM, Miller CA, Griffith M, et al. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA. 2015;314(8):811–822.
32. Pløen GG, Nederby L, Guldberg P, et al. Persistence of DNMT3A mutations at long- term remission in adult patients with AML. Br J Haematol. 2014;167(4):478–486.
33. Gaidzik VI, Weber D, Paschka P, et al.
DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia. Leukemia. 2018;32(1):30-37.
34. Jongen-Lavrencic M, Grob T, Kavelaars FG, et al. Prospective molecular MRD detection by NGS: a powerful independent predictor for relapse and survival in adults with newly diagnosed AML. Blood. 2017;130 (Suppl 1):LBA-5.
35. Chaturvedi A, Araujo Cruz MM, Jyotsana N, et al. Mutant IDH1 promotes leukemo- genesis in vivo and can be specifically tar- geted in human AML. Blood. 2013;122(16): 2877–2887.
36. Wang F, Travins J, DeLaBarre B, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentia- tion. Science. 2013;340(6132):622–626.
37. Amatangelo MD, Quek L, Shih A, et al. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood. 2017;130(6):732–741.
38. Perl AE. The role of targeted therapy in the management of patients with AML. Hematol Am Soc Hematol Educ Program. 2017;2017(1):54–65.
39. Chan SM, Thomas D, Corces-Zimmerman MR, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015;21(2):178–184.
40. Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myel- ogenous leukemia. Cancer Discov. 2016;6 (10):1106–1117.
haematologica | 2018; 103(5)
829